Live
- Seven-day national mourning in respect of Dr. Manmohan Singh
- 'I've lost a mentor and guide': Rahul Gandhi grieves demise of Dr. Manmohan Singh
- 'Great loss for all of us': President Droupadi Murmu mourns Manmohan Singh's demise
- Dr Singh presented milestone budget of 1991 which liberalised Indian economy: FM Sitharaman
- PM Modi condoles demise of Dr. Manmohan Singh
- Former Prime Minister Manmohan Singh Dies at 92: A Legacy of Economic Reforms
- Nagesh Trophy: Telangana, Gujarat dominate action on Day 4 with easy wins
- Get Ready for Dreame Technology’s Year-End Amazon Sale – Big Savings on Smart Home Products
- FIR registered as 4 voter forgery cases come to light in Delhi's Okhla constituency
- Ayodhya Ram temple to host majestic anniversary celebrations on Jan 11 with devotional, cultural programmes
Strides Pharma gets USFDA nod to market HIV drugHIV drug
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
New Delhi: Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of the company, has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the US Food & Drug Administration (USFDA), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US. Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday
